» Articles » PMID: 20006500

Tetrasubstituted Pyridines As Potent and Selective AKT Inhibitors: Reduced CYP450 and HERG Inhibition of Aminopyridines

Abstract

The synthesis and evaluation of tetrasubstituted aminopyridines, bearing novel azaindazole hinge binders, as potent AKT inhibitors are described. Compound 14c was identified as a potent AKT inhibitor that demonstrated reduced CYP450 inhibition and an improved developability profile compared to those of previously described trisubstituted pyridines. It also displayed dose-dependent inhibition of both phosphorylation of GSK3beta and tumor growth in a BT474 tumor xenograft model in mice.

Citing Articles

Combining ligand- and structure-based in silico methods for the identification of natural product-based inhibitors of Akt1.

Mahajan P, Wadhwa B, Barik M, Malik F, Nargotra A Mol Divers. 2019; 24(1):45-60.

PMID: 30798436 DOI: 10.1007/s11030-019-09924-9.


Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review).

Nitulescu G, Margina D, Juzenas P, Peng Q, Olaru O, Saloustros E Int J Oncol. 2015; 48(3):869-85.

PMID: 26698230 PMC: 4750533. DOI: 10.3892/ijo.2015.3306.


Recent advances in the development of p21-activated kinase inhibitors.

Coleman N, Kissil J Cell Logist. 2012; 2(2):132-135.

PMID: 23162744 PMC: 3490963. DOI: 10.4161/cl.21667.


Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape.

Mattmann M, Stoops S, Lindsley C Expert Opin Ther Pat. 2011; 21(9):1309-38.

PMID: 21635152 PMC: 4279453. DOI: 10.1517/13543776.2011.587959.